Biotech Startups

Canbiocin provides product development services for companies seeking to formulate and manufacture functional food or beverage products containing prebiotics, probiotics, and postbiotics. The company guides clients through the complete innovation process from concept through production and market launch.

1 investor

Cancer Focus Fund is a venture capital firm that invests in cancer-focused companies and life science ventures. The fund supports biotech and healthcare companies working on cancer treatment and research.

1 investor

Cancer Free provides personalized cancer drug testing services using blood samples to create in vitro tumor models (avatar medicine) that allow physicians to test multiple drug combinations before patient treatment. The platform serves oncologists and cancer patients across multiple drug categories including chemotherapy, hormone therapy, and targeted therapy.

1 investor

LumaBridge is an oncology-focused contract research organization (CRO) that supports outsourced clinical trials, offering services such as regulatory affairs, clinical operations, data management, medical writing, and biostatistics. It serves emerging biopharma and biotech companies developing novel oncology and immunotherapy treatments.

1 investor

Cancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.

1 investor

Emergent is a public health company that develops and manufactures medical countermeasures and protective solutions for endemic public health threats, national security preparedness, and supports biopharma innovators and organizations with manufacturing.

1 investor

Cansativa is a wholesaler of medical cannabis, supplying pharmacies, industry, and public-sector partners with cannabis products across its brands (N!CE, AMICI, Peace Naturals, Lit). Based in Germany, it focuses on distribution of medical cannabis and international market expansion within Europe.

1 investor

CanSino Biologics develops and manufactures vaccines, including tetanus, whooping cough, pneumococcal, meningococcal, and COVID-19 vaccines for prevention of infectious diseases. The company serves healthcare systems and immunization programs, primarily in China and Asia.

1 investor

Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease. The company operates in the therapeutics and biotech space.

1 investor

Cantargia is a company listed on Nasdaq Stockholm (Small Cap). The page presents shareholder and stock information, including its largest owners.

1 investor

Cantoni Therapeutics develops small molecule inhibitors targeting nicotinamide N-methyltransferase (NNMT) for the treatment of metabolic and oncology diseases. The company is a discovery and preclinical stage biotech enterprise based in the Netherlands.

1 investor

Capcyte Biotherapeutics develops surface modification technology for cardiovascular implants to improve hemocompatibility, with applications in therapeutic cell culture and other medical fields.

1 investor

Cape Haven Bio is a venture creation firm focused on translating early-stage academic discoveries into commercially viable biotech companies developing therapeutics. The firm provides strategic planning, lab infrastructure, seed capital, and consulting resources to support the progression from research to investable business.

1 investor

Capital 2B is a venture capital firm that invests in deep-tech and IP-led startups from pre-seed to Series A, writing first cheques of $200k–$3M, often as the first institutional investor. It focuses on companies at the intersection of computation, programmable biology, and advanced materials.

1 investor

Caplin Point Laboratories is a publicly listed, vertically integrated pharmaceutical company that manufactures and markets finished drug products, including injectables and ophthalmics, across therapies on the WHO essential medicines list. It sells primarily in Latin America and Francophone Africa, with a growing presence in regulated markets such as the USA and EU.

1 investor

Capricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.

1 investor

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.

1 investor

Capsigen engineers customized AAV (adeno-associated virus) capsids using its proprietary Transcription-Dependent Directed Evolution (TRADE) screening platform and data science to deliver gene therapies to specific target cells. The company develops fit-for-purpose viral vectors for treating difficult-to-treat diseases, including CNS and neuromuscular disorders.

1 investor

Capsule endoscopy medical device that captures high-resolution images of the digestive system to diagnose gastrointestinal conditions. The swallowable capsule is used to evaluate obscure bleeding, inflammatory diseases, and other GI disorders.

1 investor

Capsule AI builds life-sciences-native AI models and agentic workflows that convert unstructured scientific content—congress coverage, publications, primary research, and figures—into competitive and strategic intelligence for life science teams. Its stack includes a voice agent for HCP/patient engagements, a figure-data extraction model, and a domain-specific embedding model, deployable within an organization's existing cloud infrastructure and data lakes.

1 investor

CapyBio provides tools to measure how closely cells match a target identity and to improve them, helping scientists and biopharma teams reduce failure in drug discovery, build stronger disease models, and advance cell-based therapies. The company applies cell biology and computational methods to cell identity for research, testing, and regenerative medicine.

1 investor

1 investor

CardioMech develops a transcatheter mitral valve repair system (MVRS) that delivers artificial chords via a transfemoral, transseptal catheter approach to treat degenerative mitral regurgitation on a beating heart. The device targets heart disease patients as a less-invasive alternative to open-heart surgery and is currently for investigational use only.

1 investor

1 investor